Clinical Report: Polymorphic Ventricular Tachycardia Linked to KCNJ2 Gene Mutation
Overview
Revise to specify the benign clinical course refers to the patients' overall health.
Background
Polymorphic ventricular tachycardia is a serious arrhythmia that can lead to syncope and other complications, particularly in patients without structural heart disease. Understanding the genetic underpinnings of such arrhythmias is crucial for effective diagnosis and management. KCNJ2 mutations are linked to arrhythmias that often respond poorly to standard antiarrhythmic therapies, necessitating further exploration of treatment options.
Data Highlights
No numerical data available in the article.
Key Findings
Both patients exhibited polymorphic VT and prolonged QT intervals.
Genetic testing identified de novo KCNJ2 mutations: c.406T > C (p.S136P) in the girl and c.652C > T (p.A218T) in the boy.
Antiarrhythmic treatments were largely ineffective, with flecainide showing promise in one case.
The clinical course of arrhythmias associated with KCNJ2 mutations tends to be more benign.
Identifying mutation carriers at risk for life-threatening arrhythmias remains a challenge.
Clinical Implications
Clinicians should consider genetic testing for KCNJ2 mutations in patients presenting with polymorphic VT, especially in the absence of structural heart disease. While standard antiarrhythmic medications may be ineffective, flecainide could be a viable option for managing symptoms.
Conclusion
This case study underscores the importance of genetic evaluation in patients with polymorphic VT and highlights the need for tailored therapeutic strategies in managing KCNJ2-related arrhythmias.
